BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12429989)

  • 1. The tumour suppressor p33ING1 does not regulate migration and angiogenesis in melanoma cells.
    Cheung KJ; Li G
    Int J Oncol; 2002 Dec; 21(6):1361-5. PubMed ID: 12429989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumour suppressor p33ING1 does not enhance camptothecin-induced cell death in melanoma cells.
    Cheung KJ; Li G
    Int J Oncol; 2002 Jun; 20(6):1319-22. PubMed ID: 12012016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control.
    Garkavtsev I; Grigorian IA; Ossovskaya VS; Chernov MV; Chumakov PM; Gudkov AV
    Nature; 1998 Jan; 391(6664):295-8. PubMed ID: 9440695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.
    Riedel F; Götte K; Li M; Hörmann K; Grandis JR
    Int J Oncol; 2002 Jul; 21(1):11-6. PubMed ID: 12063543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
    La Rosa S; Uccella S; Finzi G; Albarello L; Sessa F; Capella C
    Hum Pathol; 2003 Jan; 34(1):18-27. PubMed ID: 12605362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA.
    Cheung KJ; Mitchell D; Lin P; Li G
    Cancer Res; 2001 Jul; 61(13):4974-7. PubMed ID: 11431327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of expression of vascular endothelial growth factor and matrix matalloproteinase-2 to invasion of ovarian tumor cells in vitro].
    Zhang AL; Wang SX; Lu YP; Li J; Wang CY; Ma D
    Ai Zheng; 2002 Mar; 21(3):263-6. PubMed ID: 12451991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the ING1 tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair.
    Campos EI; Martinka M; Mitchell DL; Dai DL; Li G
    Int J Oncol; 2004 Jul; 25(1):73-80. PubMed ID: 15201991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
    Benndorf R; Böger RH; Ergün S; Steenpass A; Wieland T
    Circ Res; 2003 Sep; 93(5):438-47. PubMed ID: 12881481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
    Tang Y; Nakada MT; Kesavan P; McCabe F; Millar H; Rafferty P; Bugelski P; Yan L
    Cancer Res; 2005 Apr; 65(8):3193-9. PubMed ID: 15833850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells.
    Tallen G; Riabowol K; Wolff JE
    Anticancer Res; 2003; 23(2B):1631-5. PubMed ID: 12820433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis.
    Shimizu T; Abe R; Nakamura H; Ohkawara A; Suzuki M; Nishihira J
    Biochem Biophys Res Commun; 1999 Nov; 264(3):751-8. PubMed ID: 10544003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro.
    Hoffmann S; Friedrichs U; Eichler W; Rosenthal A; Wiedemann P
    Graefes Arch Clin Exp Ophthalmol; 2002 Dec; 240(12):996-1002. PubMed ID: 12483322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
    Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation.
    Garkavtsev I; Kazarov A; Gudkov A; Riabowol K
    Nat Genet; 1996 Dec; 14(4):415-20. PubMed ID: 8944021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.